Ignite Creation Date:
2024-05-06 @ 7:57 AM
Last Modification Date:
2024-10-26 @ 11:54 AM
Study NCT ID:
NCT02631421
Status:
COMPLETED
Last Update Posted:
2019-07-16
First Post:
2014-12-12
Brief Title:
Dysregulation of Lipid Metabolism and Right Ventricular Function in PAH
Sponsor:
Vanderbilt University
Organization:
Vanderbilt University Medical Center
Study Overview
Official Title:
Dysregulation of Lipid Metabolism and Right Ventricular Function in PAH
Status:
COMPLETED
Status Verified Date:
2019-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Right ventricular RV failure is the predominant cause of death in pulmonary arterial hypertension PAH No RV-specific therapies are available in part because the underlying mechanisms of RV dysfunction are poorly understood Given the hearts preference for fatty acids FA as an energy source a deeper understanding of FA metabolism may shed light on RV adaptation to elevated afterload in PAH The purpose of this study is to test the hypothesis that defects in fatty acid metabolism are common in PAH and contribute to RV failure The investigators will measure peripheral and transcardiac lipid and glucose metabolites in PAH patients in comparison with patients with pulmonary venous hypertension and no evidence of pulmonary hypertension The investigators will also correlate metabolites with concurrent measurement of right ventricular function
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None